NNOX
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Nano-X Imaging Ltd.
- Nom
- Nano-X Imaging Ltd.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $29.4M
- Employés
- 197
- PDG
- Erez I. Meltzer
- Site web
- https://www.nanox.vision
- Marché
- CATXHCATHSDTINGNMXCTOM
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based software platform envisioned to facilitate medical screening as a service. Nano-X also operates Nanox.MARKETPLACE, a platform designed to connect imaging facilities and customers with radiologists for efficient remote interpretation of medical scans. Additionally, the company provides AI-driven software solutions to a wide range of healthcare entities, including hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers. These solutions are designed to analyze data from existing computed tomography (CT) scans to identify or predict undiagnosed or underdiagnosed medical conditions, such as osteoporosis and cardiovascular disease. Nano-X further offers Teleradiology Services, delivering remote imaging interpretation to radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities, and multi-specialty physician groups. Founded in 2011, Nano-X Imaging Ltd. is headquartered in Neve Ilan, Israel.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 83 000 titres (~76 700,00 $ US)
- Insiders
- Suesskind Dan SKainan Noga
- Total bought
-
$76,700
Avg buy (VWAP, 90d window) $0.85 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-28
- Last synced
-
2026-10-19 22:02:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Suesskind Dan S | Buy · P | 30,000 | $0.75 | $22,500 | Form 4 |
| 2026-07-28 | Kainan Noga | Buy · P | 33,000 | $0.90 | $29,700 | Form 4 |
| 2026-07-27 | Suesskind Dan S | Buy · P | 25,000 | $0.92 | $23,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
NNOX presents a deeply unfavorable risk/reward profile: severe fundamental distress (persistent operating losses, negative margins, and cash burn) overwhelms a modest liquidity cushion, yielding a weak financial…
The first sentence of the analysis written for NNOX on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 3.96 · operating margin -466% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -98.2% | -94.0% | -66.6% | -80.2% | -116.0% | |
| Ebit Margin | -466.2% | -502.9% | -602.3% | -1016.6% | -4720.7% | |
| Ebitda Margin | -376.3% | -398.9% | -481.5% | -882.4% | -4544.9% | |
| Operating Profit Margin | -466.2% | -502.9% | -631.9% | -1279.0% | -4720.7% | |
| Pretax Profit Margin | -589.9% | -477.5% | -617.0% | -1269.8% | -4742.8% | |
| Continuous Operations Profit Margin | -576.1% | -474.3% | -613.6% | -1320.2% | -4739.1% | |
| Net Profit Margin | -576.1% | -474.3% | -613.6% | -1226.9% | -4739.1% | |
| Bottom Line Profit Margin | -576.1% | -474.3% | -613.6% | -1320.2% | -4739.1% | |
| Current Ratio | 3.955 | 5.631 | 5.710 | 3.289 | 1.798 | |
| Quick Ratio | 3.773 | 5.524 | 5.558 | 3.192 | 1.739 | |
| Solvency Ratio | -2.823 | -2.001 | -2.117 | -2.516 | -0.838 | |
| Cash Ratio | 2.910 | 2.813 | 3.632 | 1.534 | 1.263 | |
| Price To Earnings Ratio | -2.414 | -7.912 | -5.898 | -3.672 | -11.359 | |
| Price To Earnings Growth Ratio | -0.088 | 0.503 | 0.127 | -0.064 | -2.310 | |
| Forward Price To Earnings Growth Ratio | -0.088 | 0.503 | 0.127 | -0.064 | -2.310 | |
| Price To Earnings Diluted Ratio | -2.414 | -7.912 | -5.898 | -3.672 | -11.359 | |
| Price To Earnings Diluted Growth Ratio | -0.088 | 0.503 | 0.127 | -0.064 | -2.310 | |
| Price To Book Ratio | 1.298 | 2.232 | 1.837 | 1.779 | 2.400 | |
| Price To Sales Ratio | 13.932 | 37.410 | 36.251 | 44.940 | 537.623 | |
| Price To Free Cash Flow Ratio | -4.031 | -10.723 | -7.468 | -7.625 | -11.450 | |
| Price To Operating Cash Flow Ratio | -4.447 | -11.533 | -8.019 | -8.885 | -18.415 | |
| Debt To Assets Ratio | 0.048 | 0.035 | 0.038 | 0.018 | 0.016 | |
| Debt To Equity Ratio | 0.056 | 0.039 | 0.043 | 0.021 | 0.020 | |
| Debt To Capital Ratio | 0.053 | 0.038 | 0.041 | 0.021 | 0.019 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.016 | 0.013 | |
| Financial Leverage Ratio | 1.161 | 1.110 | 1.118 | 1.172 | 1.243 | |
| Working Capital Turnover Ratio | 0.227 | 0.164 | 0.152 | 0.172 | 0.010 | |
| Operating Cash Flow Ratio | -2.416 | -2.619 | -2.884 | -1.730 | -0.722 | |
| Operating Cash Flow Sales Ratio | -3.133 | -3.244 | -4.521 | -5.058 | -29.196 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.103 | 1.076 | 1.074 | 1.165 | 1.608 | |
| Debt Service Coverage Ratio | -15.054 | -14.588 | -13.568 | 0.000 | -136.762 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -213.743 | |
| Short Term Operating Cash Flow Coverage Ratio | -13.008 | -11.956 | -12.830 | 0.000 | -262.559 | |
| Operating Cash Flow Coverage Ratio | -5.196 | -4.915 | -5.333 | -9.393 | -6.596 | |
| Capital Expenditure Coverage Ratio | -9.696 | -13.227 | -13.556 | -6.050 | -1.644 | |
| Dividend Paid And Capex Coverage Ratio | -9.696 | -13.227 | -13.556 | -6.050 | -1.644 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.859 | -8.669 | -6.523 | -4.646 | -10.802 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -98.2% | ▼-4.2% | ▼-7.2% |
| Ebit Margin | -466.2% | ▲36.8% | ▲995.6% |
| Ebitda Margin | -376.3% | ▲22.6% | ▲960.5% |
| Operating Profit Margin | -466.2% | ▲36.8% | ▲1054.0% |
| Pretax Profit Margin | -589.9% | ▼-112.4% | ▲949.5% |
| Continuous Operations Profit Margin | -576.1% | ▼-101.8% | ▲968.5% |
| Net Profit Margin | -576.1% | ▼-101.8% | ▲949.9% |
| Bottom Line Profit Margin | -576.1% | ▼-101.8% | ▲968.5% |
| Current Ratio | 3.955 | ▼-1.676 | ▼-0.121 |
| Quick Ratio | 3.773 | ▼-1.751 | ▼-0.184 |
| Solvency Ratio | -2.823 | ▼-0.822 | ▼-0.764 |
| Cash Ratio | 2.910 | ▲0.097 | ▲0.480 |
| Price To Earnings Ratio | -2.414 | ▲5.498 | ▲3.837 |
| Price To Earnings Growth Ratio | -0.088 | ▼-0.591 | ▲0.279 |
| Forward Price To Earnings Growth Ratio | -0.088 | ▼-0.591 | ▲0.279 |
| Price To Earnings Diluted Ratio | -2.414 | ▲5.498 | ▲3.837 |
| Price To Earnings Diluted Growth Ratio | -0.088 | ▼-0.591 | ▲0.279 |
| Price To Book Ratio | 1.298 | ▼-0.934 | ▼-0.611 |
| Price To Sales Ratio | 13.932 | ▼-23.477 | ▼-120.099 |
| Price To Free Cash Flow Ratio | -4.031 | ▲6.691 | ▲4.228 |
| Price To Operating Cash Flow Ratio | -4.447 | ▲7.086 | ▲5.813 |
| Debt To Assets Ratio | 0.048 | ▲0.013 | ▲0.017 |
| Debt To Equity Ratio | 0.056 | ▲0.017 | ▲0.020 |
| Debt To Capital Ratio | 0.053 | ▲0.015 | ▲0.019 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.006 |
| Financial Leverage Ratio | 1.161 | ▲0.050 | ▼-0.000 |
| Working Capital Turnover Ratio | 0.227 | ▲0.064 | ▲0.082 |
| Operating Cash Flow Ratio | -2.416 | ▲0.204 | ▼-0.341 |
| Operating Cash Flow Sales Ratio | -3.133 | ▲0.111 | ▲5.897 |
| Free Cash Flow Operating Cash Flow Ratio | 1.103 | ▲0.028 | ▼-0.102 |
| Debt Service Coverage Ratio | -15.054 | ▼-0.466 | ▲20.940 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲42.749 |
| Short Term Operating Cash Flow Coverage Ratio | -13.008 | ▼-1.052 | ▲47.063 |
| Operating Cash Flow Coverage Ratio | -5.196 | ▼-0.281 | ▲1.091 |
| Capital Expenditure Coverage Ratio | -9.697 | ▲3.530 | ▼-0.862 |
| Dividend Paid And Capex Coverage Ratio | -9.697 | ▲3.530 | ▼-0.862 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.859 | ▲5.810 | ▲3.840 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $181.4M | $422.1M | $359.1M | $385.5M | $701.1M | |
| Enterprise value | $140.1M | $390.2M | $311.1M | $351.7M | $640.2M | |
| EV / Sales | 10.76x | 34.59x | 31.41x | 40.99x | 490.94x | |
| EV / Op. cash flow | -3.44x | -10.66x | -6.95x | -8.11x | -16.82x | |
| EV / Free cash flow | -3.11x | -9.91x | -6.47x | -6.96x | -10.46x | |
| EV / EBITDA | -2.86x | -8.67x | -6.52x | -4.65x | -10.80x | |
| Net debt / EBITDA | 0.84x | 0.71x | 1.01x | 0.45x | 1.03x | |
| Current ratio | 3.96x | 5.63x | 5.71x | 3.29x | 1.80x | |
| Income quality | 0.54x | 0.68x | 0.74x | 0.41x | 0.62x | |
| Graham net-net | $1 | $1 | $1 | $1 | $0 | |
| Tax burden | 97.7% | 99.3% | 99.4% | 96.6% | 99.9% | |
| Interest burden | 126.5% | 94.9% | 102.4% | 124.9% | 100.5% | |
| Working capital | $49.9M | $64.7M | $73.1M | $57.4M | $42.1M | |
| Invested capital | $143.3M | $183.9M | $200.6M | $200.7M | $241.4M | |
| Return on assets | -46.3% | -25.5% | -27.8% | -41.4% | -17.0% | |
| Operating ROA | -32.6% | -26.5% | -26.5% | -35.6% | -20.5% | |
| Return on tangible assets | -73.6% | -38.2% | -44.0% | -67.8% | -30.4% | |
| Return on equity | -53.7% | -28.3% | -31.1% | -48.6% | -21.2% | |
| Return on invested capital | -39.7% | -28.2% | -30.0% | -46.2% | -19.7% | |
| Return on capital employed | -41.8% | -28.9% | -30.8% | -47.9% | -19.8% | |
| Earnings yield | -41.4% | -12.7% | -16.9% | -27.3% | -8.8% | |
| Free cash flow yield | -24.8% | -9.3% | -13.4% | -13.1% | -8.7% | |
| Capex / Op. cash flow | -10.3% | -7.6% | -7.4% | -16.5% | -60.8% | |
| Capex / Depreciation | 36.0% | 23.6% | 28.0% | 62.3% | 1010.4% | |
| Capex / Sales | 32.3% | 24.5% | 33.3% | 83.6% | 1775.9% | |
| SG&A / Sales | 208.1% | 228.2% | 286.7% | 531.9% | 3201.1% | |
| R&D / Sales | 147.7% | 178.9% | 263.0% | 309.0% | 1313.0% | |
| Stock comp / Sales | 32.2% | 64.4% | 69.0% | 217.1% | 1442.2% | |
| Intangibles / Total assets | 37.1% | 33.3% | 36.9% | 38.8% | 44.1% | |
| Days sales outstanding | 56d | 58d | 55d | 42d | 294d | |
| Days payables outstanding | 41d | 37d | 73d | 85d | 406d | |
| Operating cycle | 100d | 83d | 107d | 99d | 700d | |
| Cash conversion cycle | 59d | 46d | 34d | 13d | 294d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-16 Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026 PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today provided a brief business update and furnished certain preliminary unaudited financial data for the third quarter ended September 30, 2026. The preliminary figures are estimates based on currently available information, are preliminary and unaudited, and are subject to change upon completion of the Company''s financial close process, final adjustments, management review and other internal procedures, and review by its independent auditors.
- 2026-10-16 Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l. Agreement aims to expand the commercial reach of Nanox.AI''s Bone Solution in the Italian healthcare market. Collaboration leverages Tecnologie Avanzate''s 50 years of experience in the Italian medical technology market, established healthcare industry relationships, and expertise in introducing advanced medical technologies.
- 2026-10-15 Nanox Selected as One of TIME''s Best Inventions of 2026 for its Nanox.ARC X Nanox.ARC X recognized among the “world''s most groundbreaking innovations” and for its approach to making advanced medical imaging more accessible
- 2026-09-21 Nano-X Imaging Ltd. (NASDAQ:NNOX) Given Average Recommendation of “Moderate Buy” by Analysts Shares of Nano-X Imaging Ltd. (NASDAQ: NNOX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and
- 2026-09-10 Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd.
- 2026-09-09 Nano-X Imaging Ltd. (NNOX) Q2 2026 Earnings Call Transcript Nano-X Imaging Ltd. (NNOX) Q2 2026 Earnings Call Transcript
- 2026-09-09 Nano-X Imaging Q2 Earnings Call Highlights Nano-X Imaging NASDAQ: NNOX reported second-quarter 2026 revenue growth driven by its teleradiology, health IT and AI businesses, while recording a substantial non-cash impairment charge and outlining cost-reduction actions intended to extend its cash runway.
- 2026-09-09 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates PETACH TIKVA, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2026, and provided a business update.
- 2026-09-04 Nanox Signs Distribution Agreement with Associated X-Ray Imaging to Expand Nanox.ARC Adoption Across New England Expands Nanox''s growing U.S. distribution network with a leading New England-based medical imaging provider PETACH TIKVA, Israel — September 4 2026 — Nano-X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp., a New England-based provider of medical imaging equipment and services, specializing in X-ray, MRI, and CT systems, to support deployment of the Nanox.ARC across the region.
- 2026-08-25 Nanox to Report Second Quarter 2026 Financial Results on September 9, 2026 PETACH TIKVA, Israel, Aug. 25, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2026, before market open on Monday, September, 9, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Guy Nathanzon, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.